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Fucoidan protects hepatocytes while inhibiting HCC invasion 545displays inhibitory effects on proliferation of HCC cells and protective effects on hepatocytes. The results
suggest fucoidan is a potent suppressor of tumor invasion with hepatoprotective effects.
& 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent
cancers worldwide1. It is difﬁcult to treat because of its insensi-
tivity to chemotherapy and rapid development of drug resistance2.
Moreover, as HCC progresses, hydrophobic bile acids (BAs)
accumulate during intrahepatic cholestasis and induce apoptosis
of hepatocytes which ultimately results in liver cirrhosis or hepatic
failure3. In fact the poor prognosis of HCC patients4 is not due to
the tumor itself but to the secondary hepatic decompensation5
reﬂected in several functional HCC staging systems such as the
Barcelona Clinic Liver Cancer System6 and the Hong Kong Liver
Cancer Staging System7. For this reason, the development of a
potent HCC suppressor with a hepatoprotective effect would
represent a marked improvement in the treatment of HCC.
Fucoidan is a family of sulphated polyfucose polysaccharides
isolated from brown algae that exhibit anti-tumor8–10, anti-thrombo-
tic11, anti-inﬂammatory12 and anti-viral activities13. In particular, the
anti-cancer effects and low toxicity of fucoidan make it a potentially
valuable candidate for cancer chemotherapy14. Fucoidan effectively
suppresses cancer cell proliferation in vitro15, and inhibits metastasis
and angiogenesis of B16 melanoma xenografts and Lewis lung
adenocarcinomas in vivo9,16. More recently, it was reported to inhibit
the growth of hepatoma Huh-7 cells through down-regulation of the
chemokine ligand (CXCL)-12 at 1.0 mg/mL17. Nevertheless, the
anti-metastatic effects of fucoidan remain to be fully evaluated.
Fucoidan has also been reported to exert a protective effect on
hepatocytes showing anti-oxidative effects against acute liver injury
and liver ﬁbrosis18,19. Recently fucoidan was shown to protect
against acetaminophen-associated liver injury in vivo20. However,
the question of whether fucoidan has hepatoprotective effects
against BA-induced apoptosis has not been investigated.
In the present study, the effects and mechanism of action of
fucoidan in HCC cell invasion in vitro and in vivo and its
hepatoprotective effect against BA were evaluated. In particular,
given the importance of the hypoxic microenvironment to the
survival of HCC cells21,22, studies were carried out under normoxic
and hypoxic conditions.2. Materials and methods
2.1. Cell lines and cell culture conditions
Three human HCC cell lines were used in this study viz Huh-BAT
(a well-differentiated BA-transporter transfected HCC cell line),
Huh-7 (a well-differentiated HCC cell line), and SNU-761 (a
poorly differentiated HCC cell line)23–25. Cells were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 100,000 U/L penicillin, and
100 mg/L streptomycin with or without 100 nmol/L insulin. In
all experiments, cells were subjected to overnight serum starvationto avoid confounding variables related to serum-induced signaling.
Cells were incubated at 37 1C under either normoxic conditions
(20% O2, 5% CO2) or hypoxic conditions (1% O2, 5% CO2 and
94% N2). Fucoidan from Fucus vesiculosus was obtained from
Sigma-Aldrich Co. LLC. (Seoul, South Korea).
2.2. Animal experiments
In vivo studies were carried out in C3H mice (Orient Bio Inc). The
in vivo study protocol was approved by the Institutional Animal Care
and Use Committee (IACUC) and Ethics Committee of Seoul
National University Hospital, Central South University and all
experiments were carried out in strict accordance with the recommen-
dations of the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. Surgical procedures were performed
under anesthesia with sodium pentobarbital unless otherwise stated
and all efforts were made to minimize animal stress and suffering.
2.3. Cell proliferation analysis (MTS assay)
Cell proliferation was determined using the Cell Titer 96 Aqueous
One Solution cell proliferation assay (Promega, Madison, WI,
USA). This measures the conversion of the colorimetric reagent
3,4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium salt (MTS) into soluble formazan by
dehydrogenase enzymes found in metabolically proliferating cell.
Following each treatment, 20 μL dye solution was added to each
well of a 96-well plate and incubated for 2 h. Subsequently,
absorbance was recorded at 490 nm using an enzyme-linked
immunosorbent assay (ELISA) plate reader (Molecular Devices,
Sunnyvale, CA, USA). The half maximal inhibitory concentration
(IC50) for each cell line was calculated using the Softmax Pro plate
reader program.
2.4. Cell invasion assay
Invasion of HCC cells (Huh-7 and SNU-761) under both normoxic
and hypoxic conditions was measured in 24-well chambers. Inserts
were transferred into wells and coated with Matrigel (BD
Biosciences, Billerica, MA, USA) for 30 min at 37 1C. Cells were
then suspended in serum-free medium and implanted on the
Matrigel-coated upper chambers (5 104 cells/chamber); DMEM
containing 10% fetal bovine serum (FBS) was added to the lower
chambers. Cells were incubated for 6 h at 37 1C and then
incubated with or without fucoidan for 24 h before being stained
with 4 μg/mL calcein AM (BD Biosciences, Billerica, MA, USA)
in Hank's balanced salt solution (HBSS) at 37 1C for 90 min.
Invasion capacity was determined as relative ﬂuorescence units
measured at excitation and emission wavelengths of 494 and
517 nm respectively using a multifunctional plate reader (EnVi-
sion Multilabel Reader; PerkinElmer Inc., Waltham, MA, USA).
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HCC cells were lysed on ice for 20 min using lysis buffer and
centrifuged at 14,000 g for 10 min at 4 1C. To carry out sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
samples were transferred to nitrocellulose membranes, blotted
with appropriate primary antibodies at a dilution of 1:1000, and
treated with peroxidase-conjugated secondary antibodies (Bio-
source International, Camarillo, CA, USA). Bound antibodies
were visualized using chemiluminescent substrate (ECL; Amer-
sham, Arlington Heights, IL, USA) and exposed to Kodak
X-OMAT ﬁlm (Kodak, New Haven, CT, USA). Primary anti-
bodies included: rabbit anti-phospho-p42/44 mitogen-activated
protein kinase (MAPK), rabbit anti-caspase 9, 6, 3, and anti-
caspase 7 (cleaved) (all from Cell Signaling Technology,
Danvers, MA, USA); anti-caspase 8 (BD Biosciences, San Jose,
CA, USA); rabbit anti-N-myc downstream-regulated gene
(NDRG)-1/CAP43 (Invitrogen Corporation, Camarillo, CA,
USA). Goat anti-actin antibody was from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA, USA). Densitometric analysis was
performed with Image J software (National Institutes of Health,
Bethesda, MD, USA).2.6. Real-time polymerase chain reaction (PCR) analysis
Total ribonucleic acids (RNAs) were extracted from Huh-7 and
SNU-761 cells using Trizol reagent (Invitrogen, Carlsbad, CA,
USA). Complementary deoxyribonucleic acid (cDNA) templates
were prepared using oligo(dT) random primers and Moloney
murine leukemia virus (MoMLV) reverse transcriptase. After the
reverse transcription reaction, the cDNA template was ampliﬁed
by PCR using Taq polymerase (Invitrogen). VMP-1 was deter-
mined by real-time PCR (LightCycler; Roche Molecular Biochem-
icals, Mannheim, Germany) using SYBR green as the ﬂuorophore
(Molecular Probes, Eugene, OR, USA). After electrophoresis in
1% agarose gel, the portion of gel containing the expected PCR
product of vacuole membrane protein 1 (VMP-1) was excised
(242 bp) and the product eluted into Tris–HCl buffer using a DNA
gel extraction kit (Qiagen, Valencia, CA, USA). Forward and
reverse primers were 5′-GTGGCTTTCATTGGTGCTGTCC-3′
and 5′-GAGTTCAACCGCTGCTGGA TTC-3′, respectively. Gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expres-
sion was used as a control. The level of VMP-1 mRNA expression
was calculated as the relative intensity of the PCR product bands
compared with that from the GAPDH gene using the 2–ΔΔCt
method. All PCR experiments were performed in triplicate.2.7. SiRNA transfection
Cells were seeded in a 6-well culture plate (2 105 cells/well) in
2-mL antibiotic-free medium supplemented with 10% FBS. At
60%–80% conﬂuence, cells were transfected with small interfering
RNA (siRNA) using the siRNA transfection reagent (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) according to the
manufacturer's instructions. The cells were treated with siRNA
for 6 h at 37 1C and then growth medium containing 20% FBS and
antibiotics was added. After 18 h, the medium was replaced with
fresh medium containing 10% FBS and antibiotics and after 24 h,
the cells were used in subsequent experiments.2.8. Distant metastasis model (splenic injection)
Five-week-old male C3H mice were anesthetized with ether and
subjected to splenic injection as previously described26. After
exposing the spleen by an upper quadrant incision, 1 105
MH134 cells (a mouse hepatocellular carcinoma cell line)27 were
injected into its lower pole using a 31-gauge needle. Mice
were then treated with intraperitoneal (i.p.) injections of normal
saline (control group, n¼4) or 10 mg/kg fucoidan (treatment
group, n¼4) every two days. After eight days, the number of
macroscopic liver metastases and the sum of the maximal diameter
for each nodule were determined. The i.p. dose was determined
based on a previous study of the antitumor effects of fucoidan
in vivo28. Tumor specimens were ﬁxed in 4% formaldehyde and
embedded in parafﬁn. For immunohistochemical (IHC) analysis,
specimens were cut into 4 μm sections and subjected to IHC
staining using the anti-mouse CD31 antibody (Vector Labora-
tories, Inc., Burlingame, USA) at a 1:300 dilution or anti-glypican
(GP)-3 antibody (Novus Biologicals, Littleton, USA) at a 1:200
dilution.
2.9. Primary hepatocyte isolation and culture
Primary hepatocytes from ﬁve-week-old C3H mice were isolated
and cultured as previously described29. The mice were housed and
handled under speciﬁc pathogen-free conditions. Hanks' solution I
consisted of basal Hanks' solution containing 2.5 mmol/L EGTA,
0.1% glucose and penicillin/streptomycin at a dilution of 1:100.
Hanks' solution II consisted of basal Hanks' solution containing
0.3 mg/mL collagenase CLSII and 5 mmol/L CaCl2. Hanks'
solutions were prewarmed to 42 1C and collagenase added
immediately prior to liver perfusion. After shaving the abdomen,
the abdominal cavity was opened and the portal vein cannulated
with a 25-gauge catheter to which a silicon tube was connected.
Hanks' solution I was perfused using a peristaltic infusion pump at
a ﬂow rate of 8 mL/min. After infusion was initiated, the inferior
vena cava was incised to permit sufﬁcient outﬂow. The liver was
perfused with Hanks' solution I for 2 min followed by Hanks′
solution II for 5 min. Efﬁcient perfusion via the portal vein was
evidenced by the color change in liver from dark red-brown to
light brown. Following perfusion, the gallbladder and liver capsule
were removed using a pincette and livers transferred to sterile Petri
dishes.
After disintegrating livers by gentle shaking, suspensions were
ﬁltered through a 100 mm cell strainer and transferred to 50 mL
Falcon tubes. Cells were washed twice with William's medium E
(WME) at room temperature and 37.5 1C before being centrifuged
for 2 min and resuspended in WME. Hepatocytes were then plated
on collagen-coated culture dishes with fetal calf serum (FCS) cell
culture medium and kept in a humidiﬁed cell culture incubator at
37 1C under 5% CO2. After 4 h during which hepatocytes attached
to the collagen-coated dish, FCS medium was removed and
replaced with serum-free cell culture medium. After a further
14–20 h, cells were washed three times with starvation medium
and incubated in starvation medium for the indicated time periods.
2.10. Death-inducing signaling complex immunoprecipitation
(DISC IP)
Cell pellets were treated with lysis buffer (100 mmol/L Tris–HCl,
5 μmol/L EDTA, and 1% NP-40) containing protease inhibitor
Figure 1 Effect of fucoidan on proliferation and invasion of HCC cells. (A) Huh-7 and SNU-761 cell growth following treatment with fucoidan
(0, 0.1, 0.25, 0.5, 1, and 2 mg/mL). *Concentration used in the invasion assay; (B) Fucoidan (1 mg/mL) enhances apoptosis of Huh-7 cells under
both normoxic and hypoxic conditions; (C) Huh-7 cell invasion through a Matrigel-coated ﬁlter following treatment with fucoidan 0.1 mg/mL
under normoxic conditions and 0.5 mg/mL under hypoxic conditions; (D) SNU-761 cell invasion following treatment with fucoidan 0.1 mg/mL
under both normoxic and hypoxic conditions.
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incubated with rat anti-death receptor (DR) 5 antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), mouse anti-Fas-
associated death domain (FADD) antibody (BD Biosciences,
San Jose, CA, USA), mouse anti-cellular FLICE inhibitory protein
(cFLIP) antibody (Enzo Life Science, Farmingdale, NY, USA), or
mouse anti-caspase 8 antibody (Upstate, Lake Placid, NY, USA)
at 4 1C for 1 h. Protein A/G beads (Santa Cruz, San Diego,
CA, USA) were added to the lysate and incubated overnight
with gentle rocking at 4 1C. The beads were washed ﬁve times
by repeated suspension in 500 μL lysis buffer followed by
centrifugation at 10,000 g for 1 min. After the last wash,
35 μL Laemmli buffer (4% SDS, 20% glycerol, 10% 2-mercap-
toethanol, 0.004% bromophenol blue, 0.125 mol/L Tris HCl, pH
6.8) was added to the pellet and heated at 100 1C for 5 min.
Centrifugation was performed again to collect supernatant and
ﬁnally samples were subjected to immunoblot analysis as
described above.
2.11. Statistical analysis
Statistical analysis was performed using PASW version 18.0
(SPSS Inc., Chicago, IL, USA). All experimental results are based
on three independent experiments using cells from three separate
isolations and are presented as mean7standard deviation (SD).
For comparisons between groups, data were analyzed by the
Mann–Whitney U test or one-way ANOVA. For all tests, Po0.05
was regarded as statistically signiﬁcant.3. Results
3.1. Cell proliferation analysis (MTS assay)
The effect of 0–2 mg/mL fucoidan on Huh-7 and SNU-761 cell
growth was assessed in vitro using the MTS assay. Cell prolifera-
tion following fucoidan treatment decreased in a dose-dependent
manner under both normoxic and hypoxic conditions (Fig. 1A).
Moreover, 1 mg/mL fucoidan enhanced apoptosis of Huh-7 cells
as compared to control as shown by the expression of bax, bid,
caspase-8, -7, and -9 cleavages, under both normoxic and hypoxic
conditions (Fig. 1B). The IC50 values in Huh-7 cells were
estimated to be 0.80 mg/mL under normoxic conditions and
1.05 mg/mL under hypoxic conditions. Corresponding values in
SNU-761 cells were 0.28 and 0.6 mg/mL, respectively.
3.2. Cell invasion assay
Invasion assays were performed using a concentration of fucoidan
that did not inhibit proliferation of HCC cells (Huh-7 and SNU-
761) under normoxic and hypoxic conditions. Huh-7 cell invasion
through a Matrigel-coated ﬁlter was evaluated after treatment with
fucoidan 0.1 mg/mL under normoxic conditions and 0.5 mg/mL
under hypoxic conditions. SNU-761 cell invasion was evaluated
after treatment with fucoidan 0.1 mg/mL under both normoxic and
hypoxic conditions. At 24 h, fucoidan signiﬁcantly suppressed
Huh-7 and SNU-761 cell invasion compared to controls under
both normoxic and hypoxic conditions (Fig. 1C and D).
Figure 2 Fucoidan enhances the expression of NDRG-1/CAP43 and mesenchymal markers. Expression of NDRG-1/CAP43 and mesenchymal
markers (CK19, MMP-2, LOX, cathepsin D, vimentin, e-cadherin and ﬁbronectin) were evaluated by immunoblotting in (A) Huh-7 and (B) SNU-
761 cells and by (C) densitometric analyses (data are expressed as the relative ratio of NDRG-1/CAP43 to actin).
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by fucoidan
The expressions of NDRG-1/CAP43 (a stress-responsive protein
involved in cell growth that acts as a tumor suppressor in many
cell types) and mesenchymal markers (CK19, MMP-2, MMP-9,
LOX, cathepsin D, vimentin, E-cadherin, and ﬁbronectin) were
evaluated by immunoblotting. The expression of NDRG-1/CAP43
was higher in Huh-7 and SNU-761 cells treated with fucoidan than
in controls at 48 h (Fig. 2A and B). The up-regulation of NDRG-1/
CAP43 expression in fucoidan-treated SNU-761 cells was slightly
less prominent which may be due to the different cell lines.
Increased expression of NDRG-1/CAP43 at 48 h due to fucoidan
was also found by densitometric analysis (Fig. 2C). In contrast,
fucoidan treatment was found to decrease the expressions of
vimentin, E-cadherin, and ﬁbronectin in Huh-7 cells as compared
to controls (Fig. 2A).
In order to determine the pathway activated by fucoidan, the
expressions of total p42/44, phosphorylated-p42/44 (p-p42/44),
total Akt, and phosphorylated-Akt (p-Akt) were evaluated in HCC
cells by immunoblot assay. At early time points, the expression of
p-p42/44 was higher in Huh-7 cells compared to control cells
(Fig. 3A) and expression was also higher in SNU-761 cells
(Fig. 3B). However, changes in the expression of total Akt and
p-Akt were not consistent in the two cell lines.The effect of fucoidan on the expression of p42/44 MAPK
pathway-dependent NDRG-1/CAP43 in Huh-7 and SNU-761 cells
was also evaluated by immunoblotting and found to be attenuated
by U0126 (MAPK inhibitor) treatment (Fig. 3C). Densitometric
analysis also conﬁrmed that fucoidan activates the expression of
NDRG-1/CAP43 in a p42/44 MAPK pathway-dependent manner
(Fig. 3D).
An invasion assay was also carried out to evaluate whether
NDRG-1/CAP43 siRNA increases invasion of fucoidan-treated
HCC cells. First, the speciﬁc knockdown effect of siRNA targeting
NDRG-1/CAP43 was examined by immunoblot assay. As shown
in Fig. 4A, NDRG-1/CAP43 siRNA signiﬁcantly decreased the
expression of NDRG-1/CAP43 in Huh-7 cells. In addition,
fucoidan suppressed HCC cell invasion via NDRG-1/CAP43
under both normoxic and hypoxic conditions (Fig. 4B and C).3.4. Enhanced expression of VMP-1 by fucoidan under normoxic
conditions
The effect of fucoidan treatment on VMP-1 (a novel molecule that
inhibits metastasis and proliferation in HCC) was investigated
using quantitative real-time PCR. VMP-1 mRNA expression was
signiﬁcantly increased in SNU-761 cells (Fig. 5A), VMP-1 siRNA
signiﬁcantly decreased VMP-1 mRNA expression in both Huh-7
Figure 3 Fucoidan enhances the expression of NDRG-1/CAP43 by the p42/44 MAPK pathway. Immunoblotting reveals that fucoidan enhances
expression of phosphorylated-p42/44 (p-p42/44) in (A) Huh-7 and (B) SNU-761 cells and (C) that expression of NDRG-1/CAP43 in Huh-7 and
SNU-761 cells is attenuated by treatment with U0126 (MAPK inhibitor). (D) The outcome of densitometric analysis data are expressed as the
relative ratio of NDRG-1/CAP43 to actin.
Figure 4 Invasion of HCC cells following fucoidan treatment with NDRG-1/CAP43 siRNA. (A) Immunoblot analysis reveals that NDRG-1/
CAP43 siRNA signiﬁcantly decreases the expression of NDRG-1/CAP43 in Huh-7 cells and increased invasion of fucoidan-treated HCC cells.
Fucoidan suppresses invasion of (B) Huh-7 and (C) SNU-761 cells through NDRG-1/CAP43 activity.
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Figure 5 Fucoidan enhances expression of VMP-1 under normoxic conditions. (A) RT-PCR reveals that fucoidan signiﬁcantly increases VMP-1
mRNA expression; (B) VMP-1 siRNA signiﬁcantly decreases VMP-1 mRNA expression in both Huh-7 and SNU-761 cells; (C) VMP-1 siRNA
increases invasion of fucoidan-treated HCC cells; (D) increased expression of VMP-1 in Huh-7 cells is attenuated by U0126 (MAPK inhibitor).
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increased invasion of SNU-761 cells (Fig. 5C), all under normoxic
conditions. Thus VMP-1 appears to be involved in HCC cell
invasion but only under normoxic conditions. The increased
expression of VMP-1 in Huh-7 cells was attenuated by U0126
(MAPK inhibitor) under normoxic conditions (Fig. 5D, Po0.05).
3.5. Fucoidan inhibited liver metastasis in an intrahepatic
portal vein metastasis model in vivo
Fucoidan was anti-metastatic in the distant metastasis model as
shown by the fact that the number of intrahepatic metastases in the
fucoidan treatment group was signiﬁcantly lower than in the
control group (Fig. 6A, Po0.05). In addition, the sum of the
maximal diameter of each nodule in the fucoidan treatment group
was signiﬁcantly lower than that in the control group (Fig. 6B,
Po0.05). Fucoidan attenuated the nuclear grade of MH134 cells
as determined by hematoxylin and eosin (H&E) staining and
attenuated angiogenesis of MH134 cells as shown by decreased
CD31 expression on IHC staining (Fig. 6C). The expression of
GP-3 was also attenuated by fucoidan treatment when compared to
control.
3.6. Fucoidan suppressed BA-induced apoptosis
To evaluate whether fucoidan decreased BA-induced hepatocyte
apoptosis, the hepatoprotective effect of fucoidan on Huh-BATcells stably transfected with a BA transporter was evaluated as
previously described30–32. Fucoidan signiﬁcantly decreased BA-
induced Huh-BAT cell apoptosis as shown by attenuation of
caspase-8, -9, -3, and -7 cleavages, p-JNK, and bid as compared to
BA-treated cells (Fig. 7A). DISC-IP was used to evaluate changes
in DISC assembly and revealed that fucoidan suppressed the
mobilization of caspase-8, cFLIP, DR-5 and FADD into DISC as
compared to BA-treated cells (Fig. 7B). Decreased recruitment to
DISC leads to suppression of autocatalytic processes of the
procaspases within DISC. Finally, following BA treatment of
primary mouse hepatocytes in culture, immunoblotting showed
fucoidan signiﬁcantly decreased BA-induced hepatocyte apoptosis
as shown by the attenuation of caspase-8, and -7 cleavages
compared to BA-treated cells (Fig. 7C).4. Discussion
The present study clearly demonstrates that fucoidan, a sulphated
polysaccharide puriﬁed from brown algae, possesses anti-meta-
static effects on HCC both in vitro (Huh-7 and SNU-761 cells) and
in vivo (C3H mouse) and exerts a hepatoprotective effect by
decreasing BA-induced hepatocyte apoptosis. Fucoidan inhibited
HCC cell invasion through up-regulation of p42/44 MAPK-
dependent NDRG-1/CAP43 and partly, under normoxic condi-
tions, through up-regulation of p42/44 MAPK-dependent VMP-1.
Fucoidan also decreased the migratory potential of Huh-7 cells by
suppressing mesenchymal markers. In vivo, fucoidan decreased the
Figure 6 Fucoidan inhibits liver metastasis in the distant metastasis model. (A) The number of intrahepatic metastases in the fucoidan treatment
group and control group; (B) the sum of the maximal diameter of each nodule in the two groups; (C) histological analysis following fucoidan
treatment. The nuclear grade of MH134 cells was determined by H&E-staining and CD31 and GP-3 expression by IHC staining (200 ).
Figure 7 Fucoidan suppresses BA-induced hepatocyte apoptosis. (A) Suppression of BA-induced Huh-BAT cell apoptosis is shown by the
attenuation of caspase-8, -9, -3, and -7 cleavages, p-JNK, and bid as compared to control; (B) Suppression of the mobilization of caspase-8, cFLIP,
and FADD into DISC is shown by DISC-IP; (C) the decrease in BA-induced primary cultured-hepatocyte apoptosis as compared to BA-treated cells.
Fucoidan protects hepatocytes while inhibiting HCC invasion 551expression of the angiogenesis marker CD31. It also reduced the
expression of GP-3 which correlates with poorly-differentiated
HCC and poor prognosis33,34.NDRG-1/CAP43 (also known as Drg-1, RTP, Rit42 and
PROXY-1) regulates tumor progression in various cancers and is
involved in cell differentiation35. It is mainly expressed in non-
Yuri Cho et al.552neoplastic tissue where it is regulated by hypoxia, oxidative stress,
histone deacetylase-targeting drug, lysophosphatidylcholine, onco-
gene, and tumor suppressor gene36,37. Although some studies have
reported conﬂicting results, NDRG-1/CAP43 appears to be a
tumor suppressor or metastasis suppressor in many cancer cells
including those of breast, prostate, cervical, ovarian and pancreatic
cancers38–42. In this study, knockdown of NDRG-1/CAP43 sig-
niﬁcantly enhanced the invasion of HCC cells and its expression
was modulated by the p42/44 MAPK pathway.
As previously reported, VMP-1 is an inhibitor of cell prolifera-
tion and secretory membrane transport. Moreover, it is necessary
for autophagy and its expression induces the formation of
autophagosomes43. Interestingly, VMP-1 was signiﬁcantly up-
regulated under normoxic conditions in this study. VMP-1 was
recently identiﬁed as a membrane protein putatively associated
with suppression of HCC growth and pulmonary metastases44.
Based on our results, fucoidan appears to exert anti-metastatic
effects by up-regulation of NDRG-1/CAP43 and VMP-1 in a p42/
44 MAPK pathway-dependent manner.
The MAPK pathway usually controls proliferation of normal
and tumor cells by activation of RAS, Raf and p42/44 but there
have been some conﬂicting reports45. Very high signal intensity
of p42/44 interrupts the cell cycle by inducing cell cycle inhibitors
including p21Cip/Waf and p27KIP46. This suggests that high
signal intensity of p42/44 MAPK exerts a paradoxical effect on
tumors. In the present study, fucoidan was shown to exert anti-
metastatic effects on HCC cells by activating the p42/44 MAPK
pathway.
Surprisingly, fucoidan decreased BA-induced apoptosis of
hepatocytes while enhancing apoptosis of HCC cells. This dual
ability to preserve hepatic function may represent an ideal strategy
to treat HCC. The cytotoxic effects of hydrophobic BAs on normal
hepatocytes have been well documented and previous studies have
shown that mitochondrial dysfunction due to oxidative stress and
the non-mitochondrial nitric oxide-dependent pathway result in
hepatocyte apoptosis47,48. Procaspases are recruited to DISC via
homotypic interactions between death effector domains (DED) of
FADD and initiator caspases49 and, once recruited, undergo
autocatalytic processing50. Both the recruitment and processing
is regulated by cFLIP51. A potential mechanism by which toxic
BA promote death receptor cytotoxic signaling is by modulating
the composition of DISC52. The results of our DISC IP studies
suggest fucoidan suppresses these cascades.5. Conclusions
We have demonstrated that fucoidan displays anti-metastatic
effects on HCC through up-regulation of p42/44 MAPK-depen-
dent NDRG-1/CAP43 and protects against BA-induced apoptosis
of hepatocytes. This ability to suppress tumor invasion and exert
hepatoprotective effects suggests fucoidan may represent an ideal
therapeutic agent for the treatment of patients with HCC.References
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